Properties | Information | |
---|---|---|
PhytoCAT-ID | PhytoCAT-1944 | |
Phytochemical name or plant extracts | Ganoderic acid A (GA-A) | |
PMID | 30405790 | |
Literature evidence | Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. | |
IUPAC name | (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | |
Phytochemicals’ class or type of plant extracts | Triterpenoid | |
Source of phytochemicals or plant Extracts | Ganoderma lucidum | |
Geographical availability | NA | |
Plant parts | NA | |
Other cancers | Breast cancer | |
Target gene or protein | STAT-3 | |
Gene or Protein evidence | GA-A suppressed STAT3 target gene expression, including B cell lymphoma-extra-large and Myeloid cell leukemia 1, resulting in elevated levels of proteins associated with mitochondrial apoptosis in addition to inhibitors of cyclin-dependent kinase. | |
Target pathways | JAK-STAT3 signaling pathway | |
IC50 | NA | |
Potency | GA-A treatment inhibited breast cancer cell viability via JAK2/STAT3 downregulation and may regulate associated targets to serve an anti-MDA-MB-231 role, including mitochondrial apoptosis and regulating the expression of cell-cycle-associated factors. | |
Cell line/ mice model | MDA-MB-231 | |
Additional information | Ganoderma triterpenoids isolated from Ganoderma and has been revealed to have an effect on lymphoma growth, as well as in the promotion of cisplatin-induced cell death by inhibiting the JAK-STAT3 signaling pathway. In addition, it suppresses cancer cell proliferation and invasion and induces apoptosis in osteosarcoma | |
PubChem ID | 471002 | |
Additional PMIDs | NA | |
Additional sources of information | NA | |
Safety | NA |